Differential response rates of the CD19 CART therapy may be associated with disease burden at the time of the T-cell infusion and with Philadelphia chromosome status, regardless of pretreatment, age of the patient, and the dose of the CART-cell therapy.[21] Meanwhile, the patient recovered from CRS and the neurotoxic events caused by the CART cells. The gene discussed is CD19; the disease is congenital rubella syndrome.